NCT01984034

Brief Summary

Background: The Portuguese National Health Directorate has issued clinical practice guidelines on prescription of anti-inflammatory drugs and COX-2 inhibitors, acid suppressive therapy and proton pump inhibitors, and anti-platelets. However, their effectiveness in changing actual practice is unknown. The objectives will be to compare the effectiveness of educational outreach visits in the implementation of clinical guidelines in primary care in Portugal against usual implementation strategies and to conduct a cost-effectiveness analysis of this method. Methods: The trial will be a parallel, cluster-randomized, unblinded, trial in primary care, with a 1:1 allocation ratio. This study will assess the effect of educational outreach visits on physician compliance with prescription guidelines. The general study hypothesis is whether educational outreach visits are superior to usual implementation of guidelines regarding the reduction of inappropriate prescribing (compliance with prescription guidelines). All National Health Service primary care units in the Lisbon (Portugal) region will be invited to participate. Units will be eligible if they are using an Electronic Health Record to issue prescriptions and have at least four doctors willing to participate. Doctors in intervention units will receive three educational outreach visits (one for each guideline) during a six months period, while the control group doctors will be offered an unrelated group training session (on using the international classification for primary care). Intervention visits will be one on one 15 minutes discussions conducted by guideline authors or trained family physicians at the physician's workplace. There are two primary outcomes, measured at the physician's level. One is the proportion of COX-2 inhibitors prescribed within the entire NSAID class, in defined daily doses 18 months after the intervention. The other is the proportion of omeprazole within the entire proton pump inhibitors class, in defined daily doses at 18 months post-intervention. Prescription data will be collected from the regional pharmacy claims database.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2013

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

November 7, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 14, 2013

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

November 7, 2014

Status Verified

November 1, 2014

Enrollment Period

7 months

First QC Date

November 7, 2013

Last Update Submit

November 6, 2014

Conditions

Keywords

Educational outreachAcademic detailingGuideline adherenceFamily PracticeDrug utilizationProgram evaluationCost effectiveness

Outcome Measures

Primary Outcomes (2)

  • Proportion of COX-2 inhibitors prescribed within the entire NSAID class

    The proportion of prescriptions of COX-2 inhibitors (anatomical therapeutic classification \[ATC\] M01AH) prescribed within the entire NSAID class (ATC M01A) in defined daily doses 18 months after the intervention.

    18 months

  • Proportion of omeprazole prescribed within the entire proton pump inhibitors class

    The proportion of prescriptions of omeprazole (ATC A02BC01) within the entire proton pump inhibitors class (ATC A02BC) in defined daily doses 18 months after the intervention.

    18 months

Secondary Outcomes (7)

  • Proportion of prescriptions of COX-2 inhibitors within the NSAID class

    1 month

  • Proportion of omeprazole prescriptions of the proton pump inhibitors class

    1 month

  • Proportion of COX-2 inhibitors prescriptions within the NSAID class

    6 months

  • Proportion of omeprazole within the proton pump inhibitors class

    6 months

  • Number of defined daily doses of clopidogrel prescribed 1M

    1 month

  • +2 more secondary outcomes

Study Arms (2)

Educational Outreach Visits

EXPERIMENTAL

The intervention is three educational outreach visits, one per prescription guideline. During each 15 to 20 minutes visit an academic detailer will promote one of the guidelines to a family doctor (up to three physicians may be present in each visit if they wish to, but one to one visits will be preferred and encouraged). The detailer will also distribute a point of care summary highlighting the main messages. The detailers will be mainly Family Physicians and family medicine residents.

Behavioral: Educational Outreach Visits

Passive Dissemination

ACTIVE COMPARATOR

Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.

Other: Passive Dissemination

Interventions

The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.

Also known as: Academic Detailing
Educational Outreach Visits

Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.

Passive Dissemination

Eligibility Criteria

Age23 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Physicians of primary care unit with at least four family physicians

You may not qualify if:

  • Physicians who are planning to retire within two years
  • Physicians without an assigned patient list
  • Physicians with an incomplete patient list

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculdade Ciências Médicas Universidade Nova de Lisboa - Nova Medical School

Lisbon, Lisbon District, 1169-056, Portugal

Location

Related Publications (2)

  • Pinto D, Heleno B, Rodrigues DS, Papoila AL, Santos I, Caetano PA. Effectiveness of educational outreach visits compared with usual guideline dissemination to improve family physician prescribing-an 18-month open cluster-randomized trial. Implement Sci. 2018 Sep 5;13(1):120. doi: 10.1186/s13012-018-0810-1.

  • Pinto D, Heleno B, Rodrigues DS, Papoila AL, Santos I, Caetano PA. An open cluster-randomized, 18-month trial to compare the effectiveness of educational outreach visits with usual guideline dissemination to improve family physician prescribing. Implement Sci. 2014 Jan 15;9:10. doi: 10.1186/1748-5908-9-10.

MeSH Terms

Conditions

InflammationGastroesophageal RefluxGastrointestinal DiseasesCardiovascular Diseases

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsEsophageal Motility DisordersDeglutition DisordersEsophageal DiseasesDigestive System Diseases

Study Officials

  • Pedro A. Caetano, PhD

    Faculdade de Ciências Médicas - Universidade Nova de Lisboa (Nova Medical School)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 7, 2013

First Posted

November 14, 2013

Study Start

November 1, 2013

Primary Completion

June 1, 2014

Study Completion

December 1, 2015

Last Updated

November 7, 2014

Record last verified: 2014-11

Locations